Spots Global Cancer Trial Database for pathologic complete response
Every month we try and update this database with for pathologic complete response cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer | NCT02353858 | Rectal Cancer Locally Advance... Hyperthermia Hyperthermic Ra... Hyperthermic Ch... Deep Regional H... | Deep regional h... Radiotherapy Chemotherapy (5... | 18 Years - 80 Years | University Hospital Tuebingen | |
| Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | NCT04435197 | Esophageal Squa... | Pembrolizumab I... | 18 Years - 75 Years | Ruijin Hospital | |
| Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer | NCT06364371 | Predictive Canc... Pathologic Comp... | Medical examina... | 18 Years - 80 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC | NCT06182657 | Nasopharyngeal ... Pathologic Comp... Tumor Microenvi... | 18 Years - | Jiangxi Provincial Cancer Hospital | ||
| Improving Response to Chemotherapy by Adding Physical Exercise in the Neoadjuvant Setting of Breast Cancer Patients | NCT05976815 | Breast Cancer | Combined Aerobi... | 18 Years - | University Institute of Maia | |
| Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC | NCT05918328 | Breast Cancer HER2-positive B... | Albumin paclita... Docetaxel+Carbo... | 18 Years - 65 Years | Henan Cancer Hospital | |
| Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia | NCT05050890 | Breast Neoplasm | ctDNA level dur... | 18 Years - | Instituto Brasileiro de Controle do Cancer | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology | NCT05441098 | Breast Cancer | Neoadjuvant the... | 18 Years - | ChineseAMS | |
| Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response | NCT05371860 | Breast Cancer HER2-positive B... | Omit breast rad... | 40 Years - | Cedars-Sinai Medical Center | |
| Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET | NCT02233374 | Rectal Neoplasm... | Early MRI and P... Late MRI and PE... | 18 Years - | Royal North Shore Hospital | |
| IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer | NCT01830244 | Breast Cancer | Nab-Paclitaxel | 18 Years - | Barwon Health | |
| Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients | NCT05350722 | Breast Cancer | Single dose abl... | 50 Years - | Amsterdam UMC, location VUmc | |
| Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer | NCT02353858 | Rectal Cancer Locally Advance... Hyperthermia Hyperthermic Ra... Hyperthermic Ch... Deep Regional H... | Deep regional h... Radiotherapy Chemotherapy (5... | 18 Years - 80 Years | University Hospital Tuebingen | |
| Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer | NCT02059876 | Breast Cancer | carboplatin and... | 18 Years - | Guangdong Provincial People's Hospital | |
| IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer | NCT01830244 | Breast Cancer | Nab-Paclitaxel | 18 Years - | Barwon Health | |
| NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | NCT04335669 | Breast Cancer Triple Negative... | epirubicin, cyc... epirubicin, cyc... | 18 Years - 75 Years | Lund University Hospital | |
| Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients | NCT05350722 | Breast Cancer | Single dose abl... | 50 Years - | Amsterdam UMC, location VUmc | |
| PTC Guiding Neoadjuvant Treatment in Breast Cancer | NCT05103293 | Pathological Co... | patient-derived... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| PIK3CA in HER2+ BC and pCR Trial | NCT05750693 | HER2-positive B... | PIK3CA analysis | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients | NCT05350722 | Breast Cancer | Single dose abl... | 50 Years - | Amsterdam UMC, location VUmc | |
| Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer | NCT06364371 | Predictive Canc... Pathologic Comp... | Medical examina... | 18 Years - 80 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer | NCT01340430 | HER-2 Positive ... | Trastuzumab | 18 Years - | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer | NCT06276868 | Breast Cancer HER2-positive B... | Dalcilib+letroz... | 18 Years - 70 Years | Henan Cancer Hospital | |
| Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia | NCT05050890 | Breast Neoplasm | ctDNA level dur... | 18 Years - | Instituto Brasileiro de Controle do Cancer | |
| The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC | NCT06182657 | Nasopharyngeal ... Pathologic Comp... Tumor Microenvi... | 18 Years - | Jiangxi Provincial Cancer Hospital | ||
| Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer | NCT01566799 | Locally Advance... | Metformin | 18 Years - 70 Years | Instituto Nacional de Cancerologia de Mexico | |
| PIK3CA in HER2+ BC and pCR Trial | NCT05750693 | HER2-positive B... | PIK3CA analysis | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| RadioPathomics Artificial Intelligence Model to Predict nCRT Response in Locally Advanced Rectal Cancer | NCT04271657 | Rectal Cancer | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University | ||
| Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology | NCT05441098 | Breast Cancer | Neoadjuvant the... | 18 Years - | ChineseAMS | |
| Radiomics-based Artificial Intelligence System to Predict Neoadjuvant Treatment Response in Rectal Cancer | NCT04273477 | Rectal Cancer | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University | ||
| Post-Neoadjuvant Treatment MRI Based AI System to Predict pCR for Rectal Cancer | NCT04278274 | Rectal Cancer | artificial inte... the radiologist... | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
